Sun Yat-sen University: Carcinoma, Non-Small-Cell Lung trials

The registry lists 98 Carcinoma, Non-Small-Cell Lung studies with Sun Yat-sen University as lead sponsor. 30 are open to participants now and 3 have results posted.

Phase 1 7Phase 2 64Phase 3 11Phase 4 2No phase 19(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLCNot yet recruitingNCT07882940Phase 2
• Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLCNot yet recruitingNCT07874464Phase 2
• Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLCNot yet recruitingNCT07674524
• Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene AbnormalitiesNot yet recruitingNCT07630077Phase 2
• Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLCRecruitingNCT07609121Phase 2
• Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLCNot yet recruitingNCT07603661Phase 2
• SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLCNot yet recruitingNCT07489703Phase 2
• Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07463677Phase 2
• Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingNCT07294261Phase 2
• The IVO-LUNG StudyNot yet recruitingNCT07204548Phase 2
• Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07129161Phase 2
• A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung CancerRecruitingNCT07103395Phase 2
• Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerRecruitingNCT07086456Phase 2
• PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLCRecruitingNCT06977074Phase 2
• Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung CancerNot yet recruitingNCT06614231Phase 2
• Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain MetastasisRecruitingNCT06582940Phase 2
• Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingNCT06563999Phase 2
• Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRIRecruitingNCT06545747Phase 3
• Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary OligometastasesRecruitingNCT06542159Phase 2
• Befotertinib and Icotinib for NSCLC With Uncommon EGFR MutationsRecruitingNCT06517953Phase 2
• ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLCRecruitingNCT06426511Phase 2
• Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 MutationsNot yet recruitingNCT06054191Phase 2
• Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLCRecruitingNCT05997719
• Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerNot yet recruitingNCT05932264Phase 2
• Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsNot yet recruitingNCT05847764Phase 2
• Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation TherapyRecruitingNCT05468242Phase 2
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Phase 2
• Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLCRecruitingNCT05011487Phase 2
• Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer PatientsRecruitingNCT04980716Phase 3
• A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients TreatmentRecruitingNCT01994057
• Icotinib for Completed Resected IB NSCLC With EGFR MutationCompletedNCT02264210Phase 2Results posted
• Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung CancerStatus unknownNCT01218594Phase 2Results posted
• Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung CancerCompletedNCT01194453Phase 2Results posted
• Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)Active, not recruitingNCT06577792Not applicable
• Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)Active, not recruitingNCT06524427Not applicable
• Prognostic Significance of the Uncertain Resection in NSCLCActive, not recruitingNCT06511661
• Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.Active, not recruitingNCT06277388
• The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLCCompletedNCT06139419Phase 2
• Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain MetastasesCompletedNCT05807893Phase 2/3
• Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationActive, not recruitingNCT05491811Phase 2
• Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung CancerWithdrawnNCT05481775Phase 2
• SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung CancerActive, not recruitingNCT05319574Phase 2
• Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung CancerCompletedNCT05226728Phase 1
• Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung CancerStatus unknownNCT05016544Phase 1/2
• A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With OligoprogressionStatus unknownNCT04970693Phase 2
• MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung CancerCompletedNCT04946019Phase 2
• Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.Status unknownNCT04722406
• Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Induction Chemotherapy Plus Nivolumab and Definitive Concurrent ChemoradiotherapyCompletedNCT04654234
• Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLCStatus unknownNCT04524299Phase 2
• Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung CancerStatus unknownNCT04397926Phase 1
• Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLCCompletedNCT04345146Phase 2
• Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung CancerStatus unknownNCT04275687Phase 2
• Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following ResectionCompletedNCT04238130
• Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT04213170Phase 2
• Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung CancerCompletedNCT04212052Phase 2
• Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLCStatus unknownNCT04211090Phase 2
• A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLCStatus unknownNCT04167774Phase 2
• Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung CancerStatus unknownNCT04153799Phase 1
• Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation TherapyActive, not recruitingNCT04085250Phase 2
• Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLCStatus unknownNCT04028778Phase 3
• A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung CancerStatus unknownNCT03903887Phase 1/2
• Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLCCompletedNCT03900117Phase 2
• Study of Early Nutritional Intervention During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung CancerCompletedNCT03673657Phase 2
• Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung CancerCompletedNCT03659578Phase 2
• Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLCStatus unknownNCT03527251Phase 1
• ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGSCompletedNCT03465241
• Osimertinib as First-line Therapy for Patients With Late-stage Lung CancerStatus unknownNCT03460275Phase 2
• Explore Intra-tumor Heterogeneity and Prognostic Value of Postoperative Blood ctDNA of ⅡA - ⅢA Stage Non-squamous NSCLC Based on the Capture-based Sequencing and UMI Technology of Burning RockStatus unknownNCT03337711
• ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGSCompletedNCT03172156
• Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationStatus unknownNCT03151161Phase 2
• Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung CancerStatus unknownNCT03006575Phase 2
• A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR MutationsStatus unknownNCT02824458Phase 3
• Detection Cell Free DNA in Lung Cancer PatientsStatus unknownNCT02738593
• Paclitaxel Detection in NSCLC Treated With TC RegimenTerminatedNCT02737709Phase 2
• EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLCStatus unknownNCT02714010Phase 3
• An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer PatientsStatus unknownNCT02708667
• Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With DepressionStatus unknownNCT02650544Phase 2
• Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus TreatmentCompletedNCT02646020Phase 2
• A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI FailureStatus unknownNCT02618590
• A Prospective Multi-center Phase III Randomized Controlled TrialStatus unknownNCT02607592Phase 3
• Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung CancerCompletedNCT02573506Phase 2
• IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain MetastasesTerminatedNCT02556593Phase 2
• Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung CancerStatus unknownNCT02274337Phase 1/2
• Prognostic and Dynamic Change of CTC Enumeration in Advanced NSCLC With Chemotherapy and Targeted TherapyStatus unknownNCT02155426
• Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung CancerStatus unknownNCT02139579Phase 2
• Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationStatus unknownNCT02066038Phase 2
• Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant NsclcStatus unknownNCT01955421Phase 2
• Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT01951469Phase 3
• Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing StrategyStatus unknownNCT01891123Not applicable
• Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC PatientsStatus unknownNCT01882621Phase 3
• CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT01533727Phase 2
• Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLCCompletedNCT01528488Phase 2/3
• Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung CancerStatus unknownNCT01287962Phase 3
• A Trial on Video-assisted Thoracoscopic Surgery and Axillary Thoracotomy for Resection of Early-stage Non-small Cell Lung CancerStatus unknownNCT01102517Not applicable
• Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mgCompletedNCT01017679Phase 2
• A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of LungCompletedNCT00816868Phase 2
• Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving BisphosphonatesCompletedNCT00765687Phase 4
• Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone MetastasisCompletedNCT00762346Phase 4